Logo

People in the News: Art Krieg, Brian Gallager, Stephen Padgette

Jan 19, 2012
Premium

Startup Rana Therapeutics has named Art Krieg as its president and CEO.

Krieg was most recently an entrepreneur in residence at venture capital firm and Rana investor Atlas Venture. Before that, he served as head of Pfizer's oligonucleotide therapeutics unit.

In conjunction with the close of a Series A round of financing, Rana has also appointed two new board members: Brian Gallagher, a partner at Rana investor SR One, and Stephen Padgette, a vice president at Rana investor and ag-bio firm Monsanto.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.